Welcome to the all-new Vetlearn

  • Vetlearn is becoming part of NAVC VetFolio.
    Starting in January 2015, Compendium and
    Veterinary Technician articles will be available on
    NAVC VetFolio. VetFolio subscribers will have
    access to not only the journals, but also:
  • Over 500 hours of CE
  • Community forums to discuss tough cases
    and networking with your peers
  • Three years of select NAVC Conference
  • Free webinars for the entire healthcare team

To access Vetlearn, you must first sign in or register.


  Sign up now for:
Become a Member

Equine Winter 2006 (Vol 1, No 4)

Pathogenesis of Staphylococcus aureus Pneumonia

by Amanda M. Martabano, DVM, DACVIM, Susan L. White, DVM, MS, DACVIM, Susan Sanchez, BSc, MSc, PhD

    CETEST This course is approved for 2.0 CE credits

    Start Test


    Varying types and severities of diseases caused by Staphylococcus aureus have been reported in horses. The pathogenesis of infection and development of antimicrobial resistance pertaining to S. aureus are discussed in this article. The role of methicillin-resistant S. aureus (MRSA) in veterinary medicine is not well understood, and MRSA is an emerging problem with zoonotic potential. An 18-year-old Arabian gelding and a 2-1/2-month-old Oldenburg filly were evaluated for persistently high fevers and thrombophlebitis at The University of Georgia Veterinary Teaching Hospital. Evaluation of each horse included physical examination, complete blood cell count, serum chemistry profile, thoracic radiography, and transtracheal aspiration. In both cases, the results of transtracheal aspiration revealed S. aureus, which is an uncommon primary pathogen of the equine lower respiratory tract and was considered to be secondary to jugular thrombophlebitis.

    Staphylococcus aureus is an uncommon cause of pneumonia in horses. The results of one study1 documented isolates of S. aureus from only 1.7% of horses with bacterial pneumonia or pleuropneumonia. When staphylococcal pneumonia does occur, it can be difficult to treat. Adaptation of S. aureus to the modern hospital en­vi­ronment has been marked by the acquisition of drug resistance genes soon after antibiotics were introduced, beginning 2 years after the introduction of penicillin in 1944.2 The prevalence of methicillin-resistant S. aureus (MRSA) in nosocomial outbreaks has initiated worldwide concern. Likewise, community-acquired MRSA is emerging as a significant cause of skin infections among athletes and in state prisons.3-8 In contrast, there is limited published information regarding S. aureus infections in horses. Nosocomial MRSA infection or colonization may be a serious emerging condition in equine hospitals, as it is in human hospitals.9 Nosocomial transmission of MRSA in human hospitals is thought to occur primarily via the hands of hospital personnel contaminated by contact with infected or colonized patients.10 In horses, the nasal passages appear to be the most common site of colonization.9 Infections in horses have resulted in a range of clinical manifestations, including wound infections, surgical site infections, pneumonia, arthritis, catheter site infections, osteomyelitis, metritis, endocarditis, and dermatitis.1,9,11-14 In a 1999 study15 of a MRSA outbreak at a veterinary teaching hos­pital, concerns were raised regarding human-to-horse transmission of the organism. In that study, MRSA organisms were cultured from three of five staff members tested, and the isolates were identical to those obtained from the horses with MRSA infections.15 On the basis of the pattern associated with the infections in that outbreak, it was speculated that the hospital staff members were the primary source of the infections.15 The purpose of this article is to increase awareness of S. aureus and the signs that may result from infection.

    The Organism and Pathogenesis

    S. aureus is a gram-positive spherical coccal member of the Micrococcaceae family of bacteria. Although enterococci and bacilli are considered to be close relatives of S. aureus, staphylococcal organisms are phylogenetically unrelated to other genera in that bacterial family. Facul­tative anaerobes such as S. aureus grow by aerobic respir­ation or fermentation that yields lactic acid. All staph­ylococci are catalase positive, releasing oxygen in the presence of hydrogen peroxide. Many but not all species of staphylococci are coagulase positive, which refers to their ability to clot plasma. All S. aureus are coagulase positive; however, this is not considered a virulence factor.9 Staphylococci multiply by division in two planes, forming a cluster of cocci that morphologically distinguishes them from the chains of cocci that are typical of streptococci. The pathogenesis of S. aureus infection is multifactorial, involving surface proteins, factors that inhibit phagocytosis, and membrane-damaging toxins. The surface proteins laminin and fibronectin, which are found on epithelial and endothelial cells, form a part of the extracellular matrix and promote attachment of the cocci to host cells.16 S. aureus, aided by laminin and fibronectin, can adhere to endo­thelial cells and become internalized in a phagocytosis-like process, making it difficult to achieve effective antimicrobial concentrations because of the intracellular location of the organism. Fibronectin is also a component of blood clots. Most staphylococcal strains express a fibrinogen/fibrin-binding protein, which promotes attachment to blood clots and traumatized tissue.16 Other components of S. aureus that are purported to interfere with phagocytosis by the host are the capsular polysaccharide and protein A. Although it is hypothesized that the capsular polysaccharide (a microcapsule visualized only by electron microscopy) interferes with phagocytosis, its function is not entirely clear.16 Protein A is a surface protein that binds the Fc region of IgG, thereby interfering with opsonization and phagocytosis of the organism.

    S. aureus produces a wide variety of exoproteins that contribute to its ability to colonize and cause disease in mammalian hosts.17 Nearly all strains of S. aureus secrete enzymes and cytotoxins, including four hemolysins (i.e., a, b, g, d), lipases, hyaluronidase, nucleases, proteases, and collagenase.17 Purportedly, the main function of these proteins is to convert local host tissues into nutrients required for bacterial growth.17 Some staphylococcal strains produce additional exoproteins, including toxic shock syndrome toxin-1 (TSST-1), the enterotoxins (types A, B, C, D, E, G, H, I, J, and SEIR), the exfoliative toxins (ETs; i.e., ETA and ETB), and leukocidin.17-19 TSST-1 and the enterotoxins are known as pyrogenic toxin superantigens.16,17 Superantigens bind directly to the class II major histocompatibility complex of antigen-presenting cells outside the normal antigen-presenting groove, resulting in nonspecific stimulation of T cells.16 As a result, as many as 20% of T cells may be activated by these superantigens, whereas only 0.01% of T cells are stimulated during normal antigen presentation16 (Figure 1).

    Clinical Disease and Antimicrobial Resistance

    Superantigens are responsible for most of the severe clinical syndromes caused by S. aureus infection. Staphylococcal food poisoning in humans results from ingestion of one or more preformed enterotoxins on food contaminated with S. aureus. This food poisoning typically results in emesis, which is self-limiting in 24 to 48 hours. TSST-1 induces fever, erythroderma, cutaneous desquamation, hypotension, and multisystemic involvement.12 A TSST-1-secreting Staphylococcus sp has recently been isolated from a horse with pneumonia. The affected horse developed vasculitis, skin sloughing, and a fever that was unresponsive to NSAID therapy; the horse survived after a prolonged course of antimicrobial therapy.12

    The primary defense mechanism protecting the host against staphylococcal infection is phagocytosis of the organisms. Additional protective responses of the host include production of antibodies to neutralize the toxins and promote opsonization of the organism. From the bacterium's perspective, infection of the host is facilitated by minimizing the ability of antimicrobials to reach the organism and development of antimicrobial resistance. There are four mechanisms of bacterial resistance against antimicrobials16:

    • Enzymatic inactivation of the drug
    • Alterations within the organism that prevent the drug from binding to its target site
    • Accelerated drug efflux to prevent accumulation of effective concentrations of the antimicrobial in the bacterium
    • A bypass mechanism whereby an alternative drug-resistant version of the target within the bacterium is expressed

    Antibiotic resistance is mediated by acquisition of extrachromosomal plasmids, transposons, or other types of DNA insertion and by mutations in chromosomal genes.16

    Staphylococcal organisms have a remarkable ability to become resistant to antimicrobials, as evidenced by the acquisition of drug resistance genes soon after the organisms were exposed to new antimicrobials.2 The structural gene for methicillin (oxacillin) resistance, mecA, encodes an altered penicillin-binding protein that has reduced affinity for b-lactam antimicrobials.2 The original source of mecA in staphylococci is unknown because the gene has not been identified outside this genus.2 Oxacillin rather than methicillin is used to detect methicillin resistance because oxacillin is more resistant to degradation and is more likely to detect heteroresistant strains.20 Therefore, oxacillin-resistant S. aureus is also methicillin resistant. Most MRSA isolates are resistant to many other antimicrobial classes besides b-lactam antimicrobials.9 Resistance to antiseptics and disinfectants, such as quaternary ammonium compounds, may aid the survival of S. aureus in hospitals. Successful treatment of S. aureus infection can be hindered by antimicrobial resistance as well as abscess and scar-tissue formation, which makes it difficult to achieve effective drug concentrations at the site of infection.

    S. aureus can cause several diseases (e.g., mastitis, arthritis, suppurative disease, folliculitis, septicemia, cellulitis) in animals.1,12,21,22 Manifestations of S. aureus infection in horses include, but are not limited to, thrombophlebitis, pneumonia, and cellulitis. S. aureus pneumonia is rare in horses,1 and secondary staphylococcal infection can be terminal in horses and humans. Most life-threatening diseases caused by S. aureus infection in humans are hospital acquired and often associated with indwelling vascular devices or catheters.2,23,24 In animal hospitals, infections typically occur secondary to exposure of open skin or wounds to staphylococci, which normally colonize human nasal passages and are commensal organisms on human skin.16


    To our knowledge, S. aureus pneumonia presumed to be secondary to septic thrombophlebitis has been reported in only one equine case other than those presented in the Box 1 .25 The patient was treated with intravenous antibiotics through an indwelling catheter following hospital discharge and subsequently developed thrombophlebitis,25 a complication associated with venous catheterization and fluid therapy. Clinical signs of thrombophlebitis may include heat, swelling, pain, presence of exudate at the catheter site, and palpation of a thrombus within the affected vessel.

    The results of a retrospective study26 of horses determined that venous thrombosis was correlated with the use of locally produced fluids, fever, diarrhea, and duration of treatment. Catheter type has not been associated with phlebitis in previous studies,26 and similar types of catheters were used in the two cases reported in this article (Box 1). Our teaching hospital uses locally produced intravenous fluids to treat hospitalized patients. Although the Arabian gelding was administered locally produced polyionic fluids before the development of thrombophlebitis, the Oldenburg filly was not initially administered fluids. To decrease the risk for thrombophlebitis, all catheters in our hospital are placed while sterile gloves are worn after surgical preparation of the skin using chlorhexidine and alcohol. Extension sets are used to minimize handling of the catheter at the entrance on the skin, and catheter caps are changed daily. Catheter sites are evaluated by a clinician at least once daily, and the catheter is removed if there is evidence of local cellulitis. However, once cellulitis and phlebitis are clinically evident, secondary hematogenous spread of bacteria may be difficult to prevent. In one study27 summarizing culture results obtained from the tips of intravenous catheters, 50% of horses with normal-appearing veins had bacterial colonization of the catheter tip, whereas horses with evidence of phlebitis had a 73% frequency of bacterial colonization. Of the microorganisms isolated from catheters in that study, 19.5% were staphylococcal species—the most represented group.27

    Although strict catheter maintenance and aseptic technique may reduce the risk for infection, they do not eliminate the possibility altogether. The cases presented in this article also illustrate the severity and persistence of secondary staphylococcal infection, even in strains that demonstrate broad antimicrobial susceptibility in vitro. Although long-term antimicrobial therapy was not attempted because of financial considerations of each owner, pyrexia and malaise persisted during short-term administration of appropriate drugs based on culture and sensitivity results. In vitro sensitivities did not reveal highly resistant organisms or MRSA. The cultures revealed different strains of S. aureus in each case, which made the lack of a short-term response to antimicrobials disappointing. Long-duration antimicrobial treatment of staphylococcal infections is frequently required, and antibiotic choice is still best guided by the results of culture and sensitivity testing. In one report1 of horses with S. aureus infection, only one of five S. aureus isolates from horses with pneumonia or pleuro­pneumonia was susceptible to penicillin or ampicillin. How­ever, 80% or more of isolates in that study were sus­ceptible to b-lactamase-resistant antimicrobials, including cephalothin, aminoglycosides, and trimethoprim-sulfamethoxazole.1 Although primary pneumonia is not commonly caused by S. aureus, secondary infection from a jugular-vein catheter may be a more significant health threat to the patient.

    The zoonotic threat of MRSA in the veterinary population must be a concern of veterinary professionals.9,28,29 The evaluation of MRSA transmission between humans and animals initially revolved around the belief that MRSA was a humanotic disease—one that is transferred from humans to animals.6 More recent evidence indicates that animals can transmit MRSA to veterinary personnel, resulting in human colonization or infection.9 The current role of the environment in transmission of MRSA infection to horses or humans is unclear.11 However, relatively widespread contamination of the hospital environment occurring when infected horses are hospitalized suggests that the environment may be an important source of MRSA infection. Weese et al11 isolated MRSA from 62% of surfaces, including walls, doors, water bowls, feed bowls, and hay nets, in stalls housing MRSA-infected horses. Infection-control protocols in veterinary hospitals should be strict and well defined and must include isolation of infected patients as well as strict barrier control.


    S. aureus infection can cause a variety of clinical syndromes in humans and animals. The pathogenicity is multifactorial and is complicated by production of pyrogenic superantigens. Strains that are not multidrug resistant in vitro may still produce pyrexia and pneumonia that are difficult to control with short-term NSAID and antimicrobial therapy. MRSA is emerging with an increased frequency in veterinary populations and warrants further research.9,11 Although staphylococcal organisms are uncommon primary pathogens in the equine respiratory tract, their presence should not be overlooked because severe clinical disease may result.

    1. Sweeney CR, Holcombe SJ, Barningham SC, et al: Aerobic and anaerobic bacterial isolates from horses with pneumonia or pleuropneumonia and antimicrobial susceptibility patterns of the aerobes. JAVMA 198:839-842, 1991.

    2. Enright MC: The evolution of a resistant pathogen: The case of MRSA. Curr Opin Pharmacol 3(5):474-479, 2003.

    3. CDC: Public Health Dispatch: Outbreak of community-associated methicillin-resistant Staphylococcus aureus skin infections; Los Angeles County, 2002-2003. MMWR Morb Mortal Wkly Rep 52:88, 2003.

    4. CDC Methicillin-resistant Staphylococcus aureus skin or soft tissue infection in a state prison; Mississippi, 2000. MMWR Morb Mortal Wkly Rep 50:919-922, 2001.

    5. CDC: Methicillin-resistant Staphylococcus aureus infections among competitive sports participants; Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 52:793-795, 2003.

    6. Oughton M, Dick H, Willey BM, et al: Methicillin-resistant Staphylococcus aureus (MRSA) as a cause of infection in domestic animals: Evidence for a new humanotic disease. CBSN Newslett 1-2, 2001.

    7. Pan ES, Diep BA, Carleton HA, et al: Increasing prevalence of methicillin-resistant Staphylococcus aureus infection in California jails. Clin Infect Dis 37(10):1384-1388, 2003.

    8. Johnigan RH, Pereira KD, Poole MD: Community-acquired methicillin-resistant Staphylococcus aureus in children and adolescents: Changing trends. Arch Otolaryngol Head Neck Surg 129(10):1049-1052, 2003.

    9. Weese JS: Methicillin-resistant Staphylococcus aureus in horses and horse personnel. Vet Clin Equine 20:601-613, 2004.

    10. Bolyard EA, Talban OC, Williams WW, et al: Guideline for infection control in health care personnel, 1998. Infect Control Hosp Epidemiol 19:407-463, 1998.

    11. Weese JS, DaCosta T, Button L, et al: Isolation of methicillin-resistant Staphylococcus aureus from the environment in a veterinary teaching hospital. J Vet Intern Med 18:468-470, 2004.

    12. Holbrook TC, Munday JS, Brown CA, et al: Toxic shock syndrome in a horse with Staphylococcus aureus pneumonia. JAVMA 222:620-623, 2003.

    13. Devriese LA, Vlaminck K, Nuytten J, et al: Staphylococcus hyicus in skin lesions of horses. Equine Vet J 15(3):263-265, 1983.

    14. Sponseller BT, Ware WA: Successful treatment of staphylococcal endocarditis in a horse. Equine Vet Educ Dec:387-390, 2001.

    15. Seguin JC, Walker RD, Caron JP, et al: Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: Potential human-to-animal transmission. J Clin Microbiol 37:1459-1463, 1999.

    16. Foster T: Staphylococcus. Medmicro Chapter 12. Accessed September 2006 at http://gsbs.utmb.edu/microbook/ch012.htm.

    17. Dinges MM, Orwin PM, Schlievert PM: Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 16-34, 2000.

    18. Becker K, Friedrich AW, Lubritz G, et al: Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol 41(4):1434-1439, 2003.

    19. Omoe K, Imanishi K, Hu D, et al: Biological properties of staphylococcal enterotoxin-like toxin type R. Infect Immun 72(6):3664-3667, 2004.

    20. CDC: Laboratory detection of oxacillin/methicillin-resistant Staphylococcus aureus. Accessed September 2006 at www.cdc.gov/ncidod/dhqp/ar_lab_mrsa.html.

    21. Hnilica KA, May E: Staphylococcal pyoderma: An emerging problem. Compend Contin Educ Pract Vet 26:560-567, 2004.

    22. Markel MD, Wheat JD, Jang SS: Cellulitis associated with coagulase-positive staphylococci in racehorses: Nine cases (1975-1984). JAVMA 189(12):1600-1603, 1986.

    23. Gorenstein A, Gross E, Houri S, et al: The pivotal role of deep vein thrombophlebitis in the development of acute disseminated staphylococcal disease in children. Pediatrics 106:E87, 2000.

    24. Steinberg JP, Clark CC, Hackman BO: Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: Impact of intra­vascular devices and methicillin resistance. Clin Infect Dis 23(2):255-259, 1996.

    25. Jeffrey SC, Furr MO, Murray MJ: Staphylococcus aureus pneumonia in a mare associated with intravenous catheterisation. Equine Vet Educ 7(4):185-188, 1995.

    26. Traub-Dargatz JL, Dargatz DA: A retrospective study of vein thrombosis in horses treated with intravenous fluids in a veterinary teaching hospital. J Vet Intern Med 8:264-266, 1994.

    27. Ettlinger JJ, Palmer JE, Benson C: Bacteria found on intravenous catheters removed from horses. Vet Rec 130(12):248-249, 1992.

    28. Lee JH: Methicillin (oxacillin)-resistant Staphylococcus aureus strains isolated from major food animals and their potential transmission to humans. Appl Environ Microbiol 69(11):6489-6494, 2003.

    29. Biberstein EL, Jang SS, Hirsh DC: Species distribution of coagulase-positive staphylococci in animals. J Clin Microbiol 19(4):610-615, 1984.

    References »

    NEXT: The Editor's Desk: "The Good Old Days"

    CETEST This course is approved for 2.0 CE credits

    Start Test


    Did you know... In the 1980s, skeptics denounced the existence of Lyme disease as a discrete infectious disease. Not until the 1990s was the pathogenesis of the human disease understood.Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More